{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:30Z","timestamp":1790035050747,"version":"4.0.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon (IFN)-\u03b1 (subtypes 2a and 2b) has been used to treat MF\/SS since 1984; however, its production was recently stopped. The recombinant pegylated (PEG) form of IFN-\u03b1-2a remains the only alternative IFN treatment, although it has not been approved for use in MF\/SS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effectiveness and safety of PEG-IFN-\u03b1-2a in monotherapy and in combination with other treatments using time to next treatment (TTNT) as a measure of clinical therapeutic benefit in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an international, multicentre retrospective study of patients with MF and SS (of any stage) treated with PEG-IFN-\u03b1-2a from July 2012 to February 2022. Patients were included across 11 centres in 10 countries. The primary endpoints were to determine the TTNT of PEG-IFN-\u03b1-2a and adverse events (AEs) in MF\/SS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 105 patients were included [mean (SD) age 61 (13.1) years]; 42 (40.0%) had stage IA\u2013IIA and 63 (60.0%) had stage IIB\u2013IVB disease. PEG-IFN-\u03b1-2a was combined with other therapies in 67 (63.8%) patients, most commonly with extracorporeal photopheresis (36%) and bexarotene (22%). Patients with stage I\u2013IIA disease achieved an overall response rate (ORR) of 57%; the ORR in those with stage IIB\u2013IVB disease was 51%. Combination treatment resulted in a median TTNT of 10.4\u2005months (range 0.6\u201350.7) vs. 7.0\u2005months (range 0.7\u201352.4) for those who received monotherapy (P &amp;lt; 0.01). Overall, the mean (SD) TTNT was 9.2 (10.6) months and the ORR was 53.3% (n = 56). A complete response was seen in 13% of patients and a partial response in 40%. AEs were described in 68.6% (n = 72) of patients. Flu-like symptoms (n = 28; 26.7%), lymphopenia (n = 24; 22.9%) and elevated liver function (n = 10; 9.5%) were the most frequently reported. Grade 3\u20134 AEs were reported in 23 (21.9%) patients, mostly related to myelosuppression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PEG-IFN-\u03b1-2a for MF\/SS resulted in an ORR of 53.3% and a mean (SD) TTNT of 9.2 (10.6) months. Combination regimens were superior to monotherapy and doses of 180\u2005\u00b5g PEG-IFN-\u03b1-2a weekly were related to a higher ORR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae152","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T08:49:57Z","timestamp":1712738997000},"page":"419-427","source":"Crossref","is-referenced-by-count":21,"title":["Real-world study of pegylated interferon \u03b1-2a to treat mycosis fungoides\/S\u00e9zary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG\u00a0study"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2893-3609","authenticated-orcid":false,"given":"Keila","family":"Mitsunaga","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e9 Paris Cit\u00e9, Saint-Louis Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e9 Paris Cit\u00e9, Saint-Louis Hospital , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and Faculty of Medicine , Zurich , Switzerland"},{"name":"Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"von Gugelberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich and Faculty of Medicine , Zurich , Switzerland"},{"name":"Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine , Lausanne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petah Tikva , Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Amitay-Laish","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Rabin Medical Center \u2013 Beilinson Hospital , Petah Tikva , Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, \u2018Attikon\u2019 University General Hospital , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Jonak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Porkert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospitals of Birmingham (UHB) , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Applewaite","sequence":"additional","affiliation":[{"name":"University Hospitals of Birmingham (UHB) , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bordeaux University Hospital Center , Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsmedizin Mannheim , Mannheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Science, University of Turin Medical School , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Sanches","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo Medical School , S\u00e3o Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Cury-Martins","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo Medical School , S\u00e3o Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lora-Pablos","sequence":"additional","affiliation":[{"name":"Scientific Support Unit (i+12), Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitario 12 de Octubre , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2024081418363943000_ljae152-B1","first-page":"1","article-title":"Interferon treatment of human neoplasia","volume":"46","author":"Strander","year":"1986","journal-title":"Adv Cancer Res"},{"key":"2024081418363943000_ljae152-B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"2024081418363943000_ljae152-B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"2024081418363943000_ljae152-B4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"2024081418363943000_ljae152-B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"L\u00f3pez de Padilla","year":"2016","journal-title":"Gene"},{"key":"2024081418363943000_ljae152-B6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III \u00adinterferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"key":"2024081418363943000_ljae152-B7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2024081418363943000_ljae152-B8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1993.tb01595.x","article-title":"Interferon treatment of cutaneous T-cell lymphoma","volume":"51","author":"Ross","year":"1993","journal-title":"Eur J Haematol"},{"key":"2024081418363943000_ljae152-B9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"key":"2024081418363943000_ljae152-B10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"2024081418363943000_ljae152-B11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B12","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0190-9622(90)70054-L","article-title":"S\u00e9zary syndrome: diagnosis, prognosis, and critical review of treatment options","volume":"22","author":"Weiselthier","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"2024081418363943000_ljae152-B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1396-0296.2003.01645.x","article-title":"The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma","volume":"16","author":"Rook","year":"2003","journal-title":"Dermatol Ther"},{"key":"2024081418363943000_ljae152-B15","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"S\u00e9zary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B16","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024081418363943000_ljae152-B17","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/bjd\/ljad220","article-title":"Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in patients with leukaemic cutaneous T-cell lymphoma","volume":"189","author":"Tsai","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024081418363943000_ljae152-B19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1067\/mjd.2001.116345","article-title":"Complete molecular remission during biologic response modifier therapy for S\u00e9zary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity","volume":"45","author":"Yoo","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2024081418363943000_ljae152-B20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM198710083171506","article-title":"Lymphokines","volume":"317","author":"Dinarello","year":"1987","journal-title":"N Engl J Med"},{"key":"2024081418363943000_ljae152-B21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","article-title":"The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches","volume":"84","author":"Weiner","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024081418363943000_ljae152-B22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mjd.2001.109853","article-title":"Increased interleukin 5 production in eosinophilic S\u00e9zary syndrome: regulation by interferon alfa and interleukin 12","volume":"44","author":"Suchin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2024081418363943000_ljae152-B23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2022.02.006","article-title":"Bioconjugation strategies and clinical implications of interferon-bioconjugates","volume":"172","author":"Hauptstein","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"2024081418363943000_ljae152-B24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/vaccines9040328","article-title":"Interferon-based biopharmaceuticals: Overview on the production, purification, and formulation","volume":"9","author":"Castro","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2024081418363943000_ljae152-B25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-78771-3_30","article-title":"Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy","volume":"139","author":"Stadler","year":"1995","journal-title":"Recent Results Cancer Res"},{"key":"2024081418363943000_ljae152-B26","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon \u03b1-2a plus acitretin versus interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S\u00e9zary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J Clin Oncol"},{"key":"2024081418363943000_ljae152-B28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"8 Suppl","key":"2024081418363943000_ljae152-B29","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"2024081418363943000_ljae152-B30","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024081418363943000_ljae152-B31","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"2024081418363943000_ljae152-B32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutane\u00adous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"2024081418363943000_ljae152-B33","author":"European Medicines Agency"},{"key":"2024081418363943000_ljae152-B34","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma","volume":"31","author":"Schiller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024081418363943000_ljae152-B35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Milton Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2024081418363943000_ljae152-B36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon \u03b1-2b plus psoralen PUVA versus standard interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell \u00adlymphoma","volume":"26","author":"H\u00fcsken","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024081418363943000_ljae152-B37","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon Alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"2024081418363943000_ljae152-B38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"2024081418363943000_ljae152-B39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.det.2015.05.008","article-title":"The use of interferons in the treatment of cutaneous T-cell lymphoma","volume":"33","author":"Spaccarelli","year":"2015","journal-title":"Dermatol Clin"},{"key":"2024081418363943000_ljae152-B40","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1111\/jdv.17795","article-title":"The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides","volume":"36","author":"Patsatsi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024081418363943000_ljae152-B41","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.10306","article-title":"Use of pegylated interferon alpha-2a in cutaneous T-cell lymphoma: a retrospective case collection","author":"Gosmann","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2024081418363943000_ljae152-B42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"2024081418363943000_ljae152-B44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev"},{"key":"2024081418363943000_ljae152-B45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024081418363943000_ljae152-B46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024081418363943000_ljae152-B47","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies","volume":"7","author":"Campbell","year":"2023","journal-title":"Blood Adv"},{"issue":"s1","key":"2024081418363943000_ljae152-B48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","article-title":"Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?","volume":"79","author":"Papa","year":"1991","journal-title":"Br J Haematol"},{"key":"2024081418363943000_ljae152-B49","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/annonc\/mdf288","article-title":"Phase II trial of branched peginterferon-\u03b1 2a (40\u2005kDa) for patients with advanced renal cell carcinoma","volume":"13","author":"Motzer","year":"2002","journal-title":"Ann Oncol"},{"key":"2024081418363943000_ljae152-B50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2001.19.5.1312","article-title":"Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma","volume":"19","author":"Motzer","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024081418363943000_ljae152-B51","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2487","article-title":"Non-pegylated and pegylated interferon alpha-2a in cutaneous T-cell lymphoma and the risk of severe ocular side-effects","author":"Albrecht","year":"2022","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae152\/57955029\/ljae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/3\/419\/58820345\/ljae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/3\/419\/58820345\/ljae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:37:05Z","timestamp":1723660625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/3\/419\/7643093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae152","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,10]]}}}